Version history

{
  "session_id": "sess_SDA-2026-04-25-gapdebate-98a600b3ed_c747c608",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "codex_cli",
  "action": "critique",
  "content": "Below the central skeptical point applies to all seven: current literature strongly supports that Aβ can induce dendritic/somatodendritic tau missorting and synaptic toxicity, but it does **not** cleanly establish that the state becomes truly Aβ-independent after complete Aβ removal. Most cited evidence is either acute Aβ exposure, constitutive transgenic overexpression, or end-stage human tissue, which cannot separate “self-sustaining tau pathology” from “residual upstream injury,” incomplete Aβ clearance, or generic degeneration.\n\n1. **Fyn-anchored dendritic tau self-sustains after transient Aβ**\n- **Weak evidence:** Tau is required for Aβ/Fyn/NMDAR toxicity, but the key evidence mainly shows tau enables Aβ toxicity, not that the tau-Fyn scaffold persists after Aβ is gone. The classic mechanistic support is upstream of Aβ exposure, not post-clearance persistence.\n- **Alternative mechanisms:** Persistent calcium dysregulation could reflect irreversible spine injury, residual oligomeric Aβ, or broader membrane/trafficking damage rather than a self-maintained tau-Fyn complex.\n- **Translational risks:** Fyn inhibitors have had limited clinical traction; postsynaptic rescue in rodent neurons may not translate once human circuits have substantial synapse loss.\n- **Falsifying experiment:** Pulse human iPSC cortical neurons with labeled Aβ oligomer, then verify near-zero residual Aβ by orthogonal assays. If dendritic tau/Fyn/PSD95 colocalization and calcium pathology collapse once Aβ is truly removed, the hypothesis fails.\n\n2. **GSK3β-CDK5 feedback locks in missorting**\n- **Weak evidence:** This is biologically plausible, but one key primary neuron study found local **cdk5** activation with Aβ-induced missorting while **GSK3β was not clearly changed** in that acute setting, so the proposed dual-kinase maintenance loop may be overstated.\n- **Alternative mechanisms:** MARK/BRSK-driven polarity failure, microtubule loss, or generic stress signaling may explain persistence better than a dedicated GSK3β-CDK5 bistable loop.\n- **Translational risks:** Kinase inhibitors are pleiotropic; rescue could reflect broad suppression of stress responses rather than specific reversal of a tau-maintenance circuit.\n- **Falsifying experiment:** After transient Aβ, remove Aβ and use inducible, compartment-specific suppression of **GSK3B** and **CDK5** separately. If missorting persists despite confirmed kinase shutdown, the maintenance-loop model is weakened.\n\n3. **Proteostatic failure in dendrites traps tau after Aβ**\n- **Weak evidence:** Autophagy/endolysosomal dysfunction is common in AD, but direct evidence that **transient Aβ exposure alone** creates a durable, dendrite-localized clearance defect sufficient to maintain missorting is limited.\n- **Alternative mechanisms:** Proteostasis defects may be downstream consequences of tau accumulation, aging, APOE state, or lysosomal stress, not the primary persistence driver.\n- **Translational risks:** TFEB/autophagy manipulations often improve many proteotoxic states; a positive rescue would not uniquely support this hypothesis.\n- **Falsifying experiment:** Measure tau turnover in dendrites after Aβ washout using pulse-chase labeling plus compartment-resolved lysosomal flux. If tau clearance normalizes while missorting persists, proteostatic failure is not the main maintenance mechanism.\n\n4. **Microglia/complement sustain degeneration after Aβ clearance**\n- **Weak evidence:** Strong evidence supports complement-dependent synapse pruning in AD and microglial neurodegeneration in tauopathy, but that does not prove microglia maintain **tau missorting itself** after Aβ removal. This may explain ongoing synapse loss better than ongoing tau polarity failure.\n- **Alternative mechanisms:** Microglia could simply amplify damage initiated by tau or amyloid, while neuronal intrinsic tau seeding or excitotoxicity remains primary.\n- **Translational risks:** Microglia are state-dependent and can be protective; broad complement blockade may impair host defense and synapse remodeling.\n- **Falsifying experiment:** Clear Aβ, then deplete or reprogram microglia after missorting is established. If dendritic tau polarity remains abnormal despite reduced pruning/inflammation, the hypothesis only explains downstream degeneration, not persistence of missorting.\n\n5. **Astrocytic EAAT2 failure maintains post-Aβ dendritic stress**\n- **Weak evidence:** Astrocyte glutamate dysregulation is credible, but the direct chain “transient Aβ -> lasting astrocyte EAAT2 failure -> persistent dendritic tau missorting” is not well demonstrated. Much of the EAAT2 literature is correlational or end-stage tissue.\n- **Alternative mechanisms:** Extrasynaptic NMDAR stress could be secondary to neuronal tau pathology, microglial cytokines, seizure-like network activity, or general astrocyte reactivity rather than a specific Aβ-imprinted astrocyte state.\n- **Translational risks:** EAAT2 upregulation and NR2B antagonism are systemically messy and may not reverse established structural degeneration.\n- **Falsifying experiment:** In tri-culture, replace astrocytes after Aβ washout with naive astrocytes while keeping neurons constant. If tau missorting persists unchanged, astrocytic persistence is not required.\n\n6. **Tau missorting transitions into local tau seeding/propagation**\n- **Weak evidence:** This is one of the more plausible persistence mechanisms because tau seeding is robustly supported, but the specific bridge from **dendritic missorting** to an autonomous seeded state after a transient Aβ trigger is still mostly inferential.\n- **Alternative mechanisms:** Continued spread could still depend on low residual Aβ, inflammatory mediators, or overexpression artifacts in tau-seeding systems.\n- **Translational risks:** Anti-seeding therapies may need very early timing and may not rescue neurons already committed to degeneration.\n- **Falsifying experiment:** Use endogenous-tau neurons, transient Aβ exposure, rigorous Aβ depletion, then test whether lysates from post-washout neurons seed biosensor cells. If seeding activity disappears when Aβ is removed or when new tau synthesis is blocked, the “autonomous seeded state” claim weakens.\n\n7. **BIN1-dependent trafficking failure stabilizes somatodendritic tau**\n- **Weak evidence:** This is the weakest mechanistically. BIN1 is a strong AD risk locus and linked to tau biology, but direct evidence that BIN1 governs **resolution versus persistence** of post-Aβ tau missorting is sparse.\n- **Alternative mechanisms:** BIN1 effects may be indirect through endocytosis, membrane curvature, myelination, or cell-type-specific functions unrelated to dendritic tau retention.\n- **Translational risks:** Human BIN1 biology is isoform- and cell-type-specific; iPSC perturbations may not model the relevant neuronal context.\n- **Falsifying experiment:** Perform allele-edited isogenic iPSC neuron comparisons with endogenous tau and transient Aβ. If BIN1 genotype changes baseline trafficking but not the rate of tau re-polarization after complete Aβ removal, this hypothesis fails.\n\n**Bottom line**\nThe most defensible persistence candidates are **tau seeding/propagation (6)** and **microglia-mediated downstream degeneration (4)**, with **Fyn/NMDAR (1)** and **kinase maintenance (2)** as plausible but not yet cleanly demonstrated post-Aβ states. **BIN1 (7)** is the most speculative. The main experimental trap across all seven is failing to prove **true Aβ absence**; without that, “Aβ-independent persistence” remains unproven.\n\n**Primary sources**\n- Zempel et al., 2010, Aβ oligomers induce tau missorting, local Ca2+ rise, spine loss: https://pubmed.ncbi.nlm.nih.gov/20826658/\n- Ittner et al., 2010, dendritic tau mediates Aβ toxicity via Fyn/NMDAR pathway: https://pubmed.ncbi.nlm.nih.gov/20655099/\n- Ripoli et al., 2014, soluble Aβ oligomers drive tau mislocalization to spines and receptor signaling deficits: https://pubmed.ncbi.nlm.nih.gov/24713000/\n- Noble et al., 2003, Cdk5 as a driver of tau aggregation in vivo: https://pubmed.ncbi.nlm.nih.gov/12765608/\n- Rajendran and Paolicelli, 2018, microglia-mediated synapse loss in AD: https://pubmed.ncbi.nlm.nih.gov/29563239/\n- Shi et al., 2019, microglia drive APOE-dependent neurodegeneration in tauopathy: https://pubmed.ncbi.nlm.nih.gov/31601677/\n- Nogueras-Ortiz et al., 2023, tau-oligomer-containing synapse elimination by microglia/astrocytes in AD tissue: https://pubmed.ncbi.nlm.nih.gov/37812432/\n- Gerson and Kayed, 2013, tau oligomer seed formation and propagation: https://pubmed.ncbi.nlm.nih.gov/23882255/\n- Vasconcelos et al., 2016, Aβ can heterotypically seed tau propagation: https://pubmed.ncbi.nlm.nih.gov/26739002/\n- De Rossi et al., 2017, BIN1 and tau pathology relationship is not straightforward: https://pubmed.ncbi.nlm.nih.gov/29479533/\n\nIf you want, I can convert this into a SciDEX-ready table with fields for `support_score`, `novelty_score`, `killer_experiment`, and `skeptic_priority_rank`.",
  "tokens_used": "2251",
  "persona_id": "persona-skeptic"
}